Clinical Trial Update: Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Disitamab Vedotin in combination with Cadonilimab for HER2-mutant non-resectable biliary tract adenocarcinoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bile Duct Adenocarcinoma

Drugs mentioned

• Cadonilimab
• Disitamab Vedotin (disitamab vedotin)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Bile Duct Adenocarcinoma Non-Resectable, HER2 Gene Mutation | Phase 2 | Status: RECRUITING